CR20110673A - Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias - Google Patents

Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias

Info

Publication number
CR20110673A
CR20110673A CR20110673A CR20110673A CR20110673A CR 20110673 A CR20110673 A CR 20110673A CR 20110673 A CR20110673 A CR 20110673A CR 20110673 A CR20110673 A CR 20110673A CR 20110673 A CR20110673 A CR 20110673A
Authority
CR
Costa Rica
Prior art keywords
treatment
degenerative
inflammatory diseases
diseases
useful compound
Prior art date
Application number
CR20110673A
Other languages
English (en)
Inventor
Christel Jeanne Marie Menet
Javier Blanc
Original Assignee
Galapagos Nv
Heinz Co H J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Heinz Co H J filed Critical Galapagos Nv
Publication of CR20110673A publication Critical patent/CR20110673A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Este compuesto puede prepararse como una composición farmacéutica, y puede usarse para la prevención y el tratamiento de una diversidad de afecciones en mamíferos, que incluyen humanos, que abarcan, a modo de ejemplo, sin limitación, afecciones inflamatorias, enfermedades autoinmunitarias, enfermedades proliferativas, rechazo de trasplantes, enfermedades que involucran el deterioro del recambio de cartílago, malformaciones congénitas del cartílago y enfermedades asociadas con la hipersecreción de IL6.
CR20110673A 2009-06-26 2011-12-14 Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias CR20110673A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068509P 2009-06-26 2009-06-26
US29818810P 2010-01-25 2010-01-25

Publications (1)

Publication Number Publication Date
CR20110673A true CR20110673A (es) 2012-02-09

Family

ID=42340530

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110673A CR20110673A (es) 2009-06-26 2011-12-14 Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias

Country Status (37)

Country Link
US (2) US8796457B2 (es)
EP (2) EP2792677B1 (es)
JP (1) JP5486084B2 (es)
KR (1) KR101712561B1 (es)
CN (1) CN102459261B (es)
AR (1) AR077221A1 (es)
AU (1) AU2010264635B2 (es)
BR (1) BRPI1014759A2 (es)
CA (1) CA2765988C (es)
CL (1) CL2011003276A1 (es)
CO (1) CO6491039A2 (es)
CR (1) CR20110673A (es)
CY (1) CY1119711T1 (es)
DK (2) DK2445912T3 (es)
DO (1) DOP2011000378A (es)
EA (1) EA020111B1 (es)
ES (2) ES2634325T3 (es)
HR (2) HRP20141057T1 (es)
HU (1) HUE034205T2 (es)
IL (1) IL216618A (es)
JO (1) JO3030B1 (es)
LT (1) LT2792677T (es)
MA (1) MA33447B1 (es)
ME (1) ME01916B (es)
MX (1) MX2011013451A (es)
NZ (1) NZ596836A (es)
PE (1) PE20120494A1 (es)
PL (2) PL2445912T3 (es)
PT (2) PT2792677T (es)
RS (1) RS53617B1 (es)
SG (1) SG177359A1 (es)
SI (2) SI2792677T1 (es)
SM (2) SMT201700333T1 (es)
TW (1) TWI469981B (es)
UY (1) UY32741A (es)
WO (1) WO2010149771A1 (es)
ZA (1) ZA201109502B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JP6129155B2 (ja) 2011-04-12 2017-05-17 ライジェル ファーマシューティカルズ， インコーポレイテッド 同種移植片拒絶反応を抑制する方法
HRP20180299T1 (hr) * 2011-10-11 2018-04-20 Sanofi Biotechnology Pripravci za liječenje reumatoidnog artritisa i postupci za njihovo korištenje
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
HUE038878T2 (hu) * 2012-06-22 2018-12-28 Galapagos Nv Aminotriazolopirimidin gyulladás kezelésében történõ alkalmazásra és gyógyászati készítményeik
MA38884A1 (fr) 2013-09-05 2017-06-30 Hoffmann La Roche Composé de triazolopyridine, compositions et procédés d'utilisation associés
ES2654051T3 (es) 2013-12-05 2018-02-12 Pfizer Inc. Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
RS64677B1 (sr) * 2015-04-13 2023-11-30 Galapagos Nv Metode lečenja kardiovaskularnih poremećaja
WO2018019223A1 (zh) 2016-07-26 2018-02-01 张文燕 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途
CN111479810B (zh) * 2018-01-31 2022-11-22 珠海联邦制药股份有限公司 Jak抑制剂及其应用
MA53481A (fr) 2018-08-29 2021-07-07 Regeneron Pharma Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
CN114651010A (zh) 2019-04-24 2022-06-21 赛诺菲生物技术公司 类风湿性关节炎的诊断和治疗方法
KR20230061198A (ko) 2019-06-04 2023-05-08 사노피 바이오테크놀로지 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE283840T1 (de) 1999-01-29 2004-12-15 Chugai Pharmaceutical Co Ltd Chondrogonese promotoren und indolin-2-on derivate
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
AU2003231880A1 (en) * 2002-05-30 2003-12-19 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
JP2006517580A (ja) 2003-02-14 2006-07-27 ファイザー・プロダクツ・インク 抗炎症化合物としてのトリアゾロピリジン
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
JP2008503712A (ja) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨関節炎治療の方法及び手段
JP2008509987A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー トリアゾロピリジン化合物
MX2007004179A (es) 2004-10-07 2007-06-07 Warner Lambert Co Derivados de triazolpiridina como agentes antibacterianos.
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
ES2549862T3 (es) * 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
EP2178868A1 (en) 2007-07-18 2010-04-28 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
MX2010002312A (es) 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
US20100035875A1 (en) 2008-06-20 2010-02-11 Bing-Yan Zhu Triazolopyridine jak inhibitor compounds and methods
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
NZ597140A (en) 2009-06-05 2014-01-31 Cephalon Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物

Also Published As

Publication number Publication date
CN102459261A (zh) 2012-05-16
TWI469981B (zh) 2015-01-21
CY1119711T1 (el) 2018-06-27
HK1168098A1 (en) 2012-12-21
CO6491039A2 (es) 2012-07-31
JP5486084B2 (ja) 2014-05-07
DK2445912T3 (da) 2014-11-10
LT2792677T (lt) 2017-07-25
ES2519170T3 (es) 2014-11-06
ME01916B (me) 2015-05-20
DK2792677T3 (en) 2017-07-10
US8796457B2 (en) 2014-08-05
ES2634325T3 (es) 2017-09-27
HRP20171024T1 (hr) 2017-10-06
EP2792677B1 (en) 2017-04-26
PE20120494A1 (es) 2012-05-17
EP2792677A1 (en) 2014-10-22
HK1202537A1 (en) 2015-10-02
EP2445912A1 (en) 2012-05-02
AU2010264635B2 (en) 2015-05-07
CA2765988A1 (en) 2010-12-29
MX2011013451A (es) 2012-04-30
US9505754B2 (en) 2016-11-29
SG177359A1 (en) 2012-02-28
SMT201700333T1 (it) 2017-09-07
ZA201109502B (en) 2012-09-26
SI2792677T1 (sl) 2017-08-31
TW201103937A (en) 2011-02-01
KR101712561B1 (ko) 2017-03-06
CN102459261B (zh) 2014-11-05
US20150031671A1 (en) 2015-01-29
CL2011003276A1 (es) 2012-08-31
PL2445912T3 (pl) 2015-02-27
AU2010264635A1 (en) 2011-12-22
JO3030B1 (ar) 2016-09-05
EA201270076A1 (ru) 2012-08-30
PT2792677T (pt) 2017-07-06
HUE034205T2 (en) 2018-01-29
NZ596836A (en) 2013-02-22
IL216618A0 (en) 2012-02-29
BRPI1014759A2 (pt) 2016-04-19
HRP20141057T1 (en) 2015-03-13
AR077221A1 (es) 2011-08-10
UY32741A (es) 2011-01-31
WO2010149771A1 (en) 2010-12-29
KR20120059487A (ko) 2012-06-08
MA33447B1 (fr) 2012-07-03
IL216618A (en) 2014-09-30
CA2765988C (en) 2017-08-29
EP2445912B1 (en) 2014-08-13
SI2445912T1 (sl) 2014-12-31
RS53617B1 (sr) 2015-04-30
EA020111B1 (ru) 2014-08-29
PL2792677T3 (pl) 2017-09-29
DOP2011000378A (es) 2012-02-15
US20100331359A1 (en) 2010-12-30
JP2012530767A (ja) 2012-12-06
PT2445912E (pt) 2014-11-07
SMT201400169B (it) 2015-01-15

Similar Documents

Publication Publication Date Title
CO6491039A2 (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias
ECSP12011626A (es) 5-fenil-[1,2,4 ] triazolo [ 1,5-a ] piridin-2-il carboxamidas como inhibidores de jak
MX2013012281A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
CR20140583A (es) Aminotriazolopirimidina para uso en tratamiento de inflamación y composiciones farmacéuticas de la misma
TW201613601A (en) Pharmaceutical compositions for the treatment of inflammatory disorders
MX2016010068A (es) Sales novedosas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios.
AR089960A1 (es) Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias
CL2013000675A1 (es) Compuestos derivados de pirazolamida sustituidas, con actividad sobre pge2/ep4; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esclerosis multiple y la artritis reumtoide.
GB201013307D0 (en) Anti-microbial metal organic framework
CL2012002627A1 (es) Metodos para aumentar la tolerancia al estres abiotico y/o reducir las consecuencias del estres abiotico en plantas que comprende ponerla en contacto con una composicion que contiene acido dicarboxilico o un derivado.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CL2013002446A1 (es) Compuestos derivados de quinolin-triazolopiridin-etilpirrolidina, como inihibidores de cinasa pim; proceso para su preparacion; compuestos intermediarios; composicion que los comprende, util para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como esclerosis multiple y lupus, y para el tratamiento del cancer.
BR112014015905A2 (pt) composição
UY34210A (es) Composiciones, métodos y sistemas para la micropropagación de plantas
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
MX352727B (es) Tratamiento de trastorno autoinmune al usar agonistas de rxr.
PH12016501677A1 (en) Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CL2013000331A1 (es) Compuestos derivados de triazina-1,2 diazol condezada o de triazina-1,2,4-triazol condensada; proceso para preparar estos compuestos; composicion farmaceutica; proceso para preparar esta composicion farmaceutica; y su uso para el tratamiento de una infeccion bacteriana tal como una infeccion por la bacteria clostridium.
EA201270547A1 (ru) Фармацевтическая композиция
UA105796C2 (uk) Сполука, застосовна для лікування дегенеративних і запальних захворювань
CR11693A (es) 2-alquinil-6-pridin-2-il-piridazinonas, 2-alquinil-6-piridin-2-il-dihidropiridazinonas, 2-alquinil-6-pirimidin-2-il-piridazinonas y 2-alquinil-6-pirimidin-2-il-dihidropiridazinonas y su uso como fungicidas
AR079238A1 (es) Uso de defensinas para el tratamiento de endocarditis infecciosa
CL2011002207S1 (es) Bloqueador de torque para tuercas.